Yeah, we all know about the extremely high expenditure and no-one knows those cost are going except to the "high employee salary due to restructure as mentioned in H1", but they've got their product to commercialisation after doing all the high cost in the development stage so they aren't really classified as a start-up/spec stock, IMO.
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-129
-
- There are more pages in this discussion • 439 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.49 |
Change
0.490(4.08%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $12.11 | $12.49 | $11.50 | $155.8K | 13.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175 | $11.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.49 | 77 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |